Secondary Logo

Institutional members access full text with Ovid®

Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration–Resistant Prostate Cancer Patient With a Transplanted Kidney

Norouzi, Ghazal, MD*; Aghdam, Ramin Akbarian, MD*; Hashemifard, Hamidreza, MD; Pirayesh, Elahe, MD*

doi: 10.1097/RLU.0000000000002508
Interesting Images

A 68-year-old man with metastatic castration-resistant prostate cancer and widespread bone metastases as well as a history of kidney transplant, underwent 5 cycles of 177Lu–prostate-specific membrane antigen 617 therapies in our department. Being more cautious of the radiation burden imposed on the transplanted kidney, a lower average dose of 4 GBq per cycle was administered (instead of the more routine 6.0-7.4 GBq per cycle). However, excellent response was noted and serum creatinine level of 0.8 mg/dL remained stable.

From the *Department of Nuclear Medicine, Shohada e Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences; and

Department of Radiation Oncology, Gandi Hospital, Tehran, Iran.

Received for publication December 30, 2018; revision accepted January 12, 2019.

Conflict of interest and sources of funding: none declared.

Correspondence to: Elahe Pirayesh, MD, Address: Nuclear Medicine Department, Shohada e Tajrish Medical Center, Tajrish Sq, Tehran, Iran. E-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.